Use of molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, in chronic kidney disease-associated anemia in cats.

ABSTRACT:

Background

Erythropoietic effects of molidustat, a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, were previously demonstrated in healthy cats.

Objective

To evaluate the safety and erythropoietic effects of daily PO administration of molidustat in anemic cats with chronic kidney disease (CKD).

Animals

Twenty-one client-owned CKD cats (4-17 years old) with anemia.

Methods

Multicenter field study; randomized, masked, and placebo-controlled. Cats were treated PO once daily for 28 days with suspensions of control product (CP; n = 6) or 5 mg/kg of molidustat (n = 15). Hematocrit (HCT) was evaluated at weekly intervals. Individual cat treatment success was defined as a ≥4% point increase in HCT compared to baseline.

Results

Control group mean

SUBMITTER: Charles S 

PROVIDER: S-EPMC10800191 | biostudies-literature | 2024 Jan-Feb

REPOSITORIES: biostudies-literature